Medisyn has created intellectual property for clients in a number of therapeutic areas. In addition, Medisyn has an IP portfolio of its own oncology candidates that are available for out-license. 

DescriptionCountry of IssueDateSerial NumberTherapeutic Category
Therapeutic agents and corresponding treatments (MT103 + 6 analogs)USJuly 19, 2005US 6,919,376NSCLC/PKC Inhibition
Therapeutic agents and corresponding treatments (MT103 + 6 analogs)CanadaApril 19, 2011CA 2,499,523NSCLC/PKC Inhibition
Therapeutic agents and corresponding treatments (MT103 + 6 analogs)JapanMarch 5, 2010JP No. 4469720NSCLC/PKC Inhibition
Therapeutic agents and corresponding treatments (MT103 + 6 analogs)FranceMarch 12, 2008EU Patent 02792178.2NSCLC/PKC Inhibition
Therapeutic agents and corresponding treatments (MT103 + 6 analogs)Germany March 12, 2008EU Patent 02792178.2NSCLC/PKC Inhibition
Therapeutic agents and corresponding treatments (MT103 + 6 analogs)Switzerland March 12, 2008EU Patent 02792178.2NSCLC/PKC Inhibition
Therapeutic agents and corresponding treatments (MT103 + 6 analogs)UK March 12, 2008EU Patent 02792178.2NSCLC/PKC Inhibition
Therapeutic agents and corresponding treatments (MT477 + analogs)USJanuary 26, 2010US 7,652,029lPancreatic/Ras Pathway
Therapeutic agents and corresponding treatments (additional analogs of MT477)US ContinuationJanuary 3, 2012US 8,088,785Pancreatic/Ras Pathway
Therapeutic agents and corresponding treatments (MT477 + analogs)CanadaPending2573190Pancreatic/Ras Pathway
Therapeutic agents and corresponding treatments (MT477 + analogs)JapanJuly 27, 2012JP No. 5049124Pancreatic/Ras Pathway
Therapeutic agents and corresponding treatments (MT477 + analogs)EuropePending5765609.2Pancreatic/Ras Pathway
Therapeutic agents and corresponding treatments (MT477)ChinaNovember 23, 2011CN No. 867517Pancreatic/Ras Pathway